GLP-1 drugs linked to lower risk of obesity-related cancers: study

Major findings from ASCO 2026

A new wave of data presented at the American Society of Clinical Oncology (ASCO) 2026 meeting has revealed a striking benefit of GLP-1 receptor agonists. These drugs, already widely used for diabetes and weight loss, appear to significantly lower the risk of developing obesity-related cancers.

Researchers presented analyses from large observational studies and early trial data. The findings show a notable reduction in the incidence of cancers such as colorectal, endometrial, and kidney cancer among patients taking GLP-1 drugs compared to those on other glucose-lowering or weight-loss therapies.

How the drugs may work

Obesity is a well-established driver of cancer risk, linked to chronic inflammation, hormonal imbalances, and metabolic dysfunction. GLP-1 agonists help patients lose substantial weight and improve metabolic health, which likely underlies the cancer risk reduction.

Dr. Gilberto de Lima Lopes, a leading oncologist who presented a structured summary of the ASCO data, told Medscape that the evidence is compelling. “We are seeing a consistent signal across multiple cancer types,” he said. “This could change how we think about cancer prevention in high-risk populations.”

Experts weigh in on the evidence

Dr. David Fajgenbaum, a physician-scientist known for his work on rare immune diseases, highlighted the emerging link between GLP-1 drugs and cancer outcomes. Speaking at the conference, he noted that the anti-inflammatory effects of these drugs may play a role beyond mere weight loss.

“The data suggest a direct biological effect on cancer pathways,” Fajgenbaum said. “We need more mechanistic studies, but the clinical signal is hard to ignore.” Not all experts are convinced. Some caution that observational data can be skewed by patient selection. Healthier individuals may be more likely to stay on GLP-1 therapy, skewing the results.

Implications for clinical practice

If confirmed in randomized controlled trials, these findings could reshape guidelines for cancer prevention. Doctors may soon consider prescribing GLP-1 agonists not just for diabetes or weight management, but specifically to lower cancer risk in obese patients.

India, with its rapidly rising obesity rates and cancer burden, stands to benefit significantly. The country has seen a surge in metabolic disorders, and affordable access to these drugs remains a challenge. However, generic versions are expected in the coming years.

What remains unknown

The current studies mainly involved Western populations. Researchers are yet to confirm whether the benefits extend uniformly to Indian and other Asian populations, who may have different body compositions and cancer profiles. Long-term safety data is also limited, as GLP-1 drugs have only been in widespread use for about a decade.

Dr. Lopes emphasised that the data is not yet practice-changing. “We need prospective trials with cancer as a primary endpoint,” he said. “But for now, this is a very promising signal.”

The next step for researchers is to design trials that specifically test GLP-1 agonists for cancer prevention in high-risk groups. If those results align with the current evidence, these drugs could become a frontline tool in oncology.